[
  {
    "objectID": "joco.html",
    "href": "joco.html",
    "title": "Journal of Cutaneous Oncology",
    "section": "",
    "text": "Current Issue\n\n\n\n2023, Volume: 1, Issue 3\n\n\nAbout the Journal\nThe Journal of Cutaneous Oncology (JoCO) is an open access journal whose scope is specific to skin cancer. Currently we publish a regular “Perspectives on the Science”, in which we provide commentary on publications reviewed in our multi-institutional SoCO Journal Club. The comments in this article represent the views of the authors of this Perspectives on the Science piece. It does not represent views of any other members of the CCO or the affiliated institutions."
  },
  {
    "objectID": "jc.html#articles-1",
    "href": "jc.html#articles-1",
    "title": "Journal Club",
    "section": "2023 Articles",
    "text": "2023 Articles\n\n\n\n\n\n\nJanuary - March 2023\n\n\n\n\n\n\nMarch\nAllen, Nicholas C., Andrew J. Martin, Victoria A. Snaidr, Renee Eggins, Alvin H. Chong, Pablo Fernandéz-Peñas, Douglas Gin, et al. 2023. \"Nicotinamide for Skin-Cancer Chemoprevention in Transplant Recipients.\" New England Journal of Medicine 388 (9): 804–12. https://doi.org/10.1056/nejmoa2203086.\n\n\nFebruary\nAscierto, Paolo A, Daniil Stroyakovskiy, Helen Gogas, Caroline Robert, Karl Lewis, Svetlana Protsenko, Rodrigo P Pereira, et al. 2023. “Overall Survival with First-Line Atezolizumab in Combination with Vemurafenib and Cobimetinib in BRAFV600 Mutation-Positive Advanced Melanoma (IMspire150): Second Interim Analysis of a Multicentre, Randomised, Phase 3 Study.” The Lancet Oncology 24 (1): 33–44. https://doi.org/10.1016/s1470-2045(22)00687-8.\n\n\nJanuary\nRohaan, Maartje W., Troels H. Borch, Joost H. van den Berg, Özcan Met, Rob Kessels, Marnix H. Geukes Foppen, Joachim Stoltenborg Granhøj, et al. 2022. “Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma.” New England Journal of Medicine 387 (23): 2113–25. https://doi.org/10.1056/nejmoa2210233."
  },
  {
    "objectID": "jc.html#articles-2",
    "href": "jc.html#articles-2",
    "title": "Journal Club",
    "section": "2022 Articles",
    "text": "2022 Articles\n\n\n\n\n\n\nJanuary - December 2022\n\n\n\n\n\n\nDecember\nAmaria, Rodabe N., Michael Postow, Elizabeth M. Burton, Michael T. Tezlaff, Merrick I. Ross, Carlos Torres-Cabala, Isabella C. Glitza, et al. 2022. “Neoadjuvant Relatlimab and Nivolumab in Resectable Melanoma.” Nature 611 (7934): 155–60. https://doi.org/10.1038/s41586-022-05368-8.\n\n\nNovember\nKim, Sungjune, Evan Wuthrick, Dukagjin Blakaj, Zeynep Eroglu, Claire Verschraegen, Ram Thapa, Matthew Mills, et al. 2022. “Combined Nivolumab and Ipilimumab with or Without Stereotactic Body Radiation Therapy for Advanced Merkel Cell Carcinoma: A Randomised, Open Label, Phase 2 Trial.” The Lancet 400 (10357): 1008–19. https://doi.org/10.1016/s0140-6736(22)01659-2.\n\n\nOctober\nGross, Neil D., David M. Miller, Nikhil I. Khushalani, Vasu Divi, Emily S. Ruiz, Evan J. Lipson, Friedegund Meier, et al. 2022. “Neoadjuvant Cemiplimab for Stage II to IV Cutaneous Squamous-Cell Carcinoma.” New England Journal of Medicine387 (17): 1557–68. https://doi.org/10.1056/nejmoa2209813.\n\n\nAugust\nReijers, Irene L. M., Alexander M. Menzies, Alexander C. J. van Akkooi, Judith M. Versluis, Noëlle M. J. van den Heuvel, Robyn P. M. Saw, Thomas E. Pennington, et al. 2022. “Personalized Response-Directed Surgery and Adjuvant Therapy After Neoadjuvant Ipilimumab and Nivolumab in High-Risk Stage III Melanoma: The PRADO Trial.” Nature Medicine 28 (6): 1178–88. https://doi.org/10.1038/s41591-022-01851-x.\n\n\nJuly\nRuiz, Emily S., Kylee J. B. Kus, Timothy D. Smile, Fadi Murad, Guohai Zhou, Evelyn O. Ilori, Jonathan D. Schoenfeld, et al. 2022. “Adjuvant Radiation Following Clear Margin Resection of High T-Stage Cutaneous Squamous Cell Carcinoma Halves the Risk of Local and Locoregional Recurrence: A Dual-Center Retrospective Study.” Journal of the American Academy of Dermatology 87 (1): 87–94. https://doi.org/10.1016/j.jaad.2022.03.044.\n\n\nJune\nLiu, Kevin X., Michael G. Milligan, Jonathan D. Schoenfeld, Roy B. Tishler, Andrea K. Ng, Phillip M. Devlin, Elliott Fite, et al. 2022. “Characterization of Clinical Outcomes After Shorter Course Hypofractionated and Standard-Course Radiotherapy for Stage I-III Curatively-Treated Merkel Cell Carcinoma.” Radiotherapy and Oncology 173 (August): 32–40. https://doi.org/10.1016/j.radonc.2022.05.012.\n\n\nMay\nLuke, Jason J, Piotr Rutkowski, Paola Queirolo, Michele Del Vecchio, Jacek Mackiewicz, Vanna Chiarion-Sileni, Luis de la Cruz Merino, et al. 2022. “Pembrolizumab Versus Placebo as Adjuvant Therapy in Completely Resected Stage IIB or IIC Melanoma (KEYNOTE-716): A Randomised, Double-Blind, Phase 3 Trial.” The Lancet 399 (10336): 1718–29. https://doi.org/10.1016/s0140-6736(22)00562-1.\n\n\nApril\nQian, David C, Troy Kleber, Brianna Brammer, Karen M Xu, Jeffrey M Switchenko, James R Janopaul-Naylor, Jim Zhong, et al. 2021. “Effect of Immunotherapy Time-of-Day Infusion on Overall Survival Among Patients with Advanced Melanoma in the USA (MEMOIR): A Propensity Score-Matched Analysis of a Single-Centre, Longitudinal Study.” The Lancet Oncology 22 (12): 1777–86. https://doi.org/10.1016/s1470-2045(21)00546-5.\n\n\nMarch\nMcEvoy, Aubriana M., Kristina Lachance, Daniel S. Hippe, Kelsey Cahill, Yasman Moshiri, Christopher W. Lewis, Neha Singh, et al. 2022. “Recurrence and Mortality Risk of Merkel Cell Carcinoma by Cancer Stage and Time From Diagnosis.” JAMA Dermatology 158 (4): 382. https://doi.org/10.1001/jamadermatol.2021.6096.\n\n\nFebruary\nTawbi, Hussein A., Dirk Schadendorf, Evan J. Lipson, Paolo A. Ascierto, Luis Matamala, Erika Castillo Gutiérrez, Piotr Rutkowski, et al. 2022. “Relatlimab and Nivolumab Versus Nivolumab in Untreated Advanced Melanoma.” New England Journal of Medicine 386 (1): 24–34. https://doi.org/10.1056/nejmoa2109970.\n\n\nJanuary\nPostow, Michael A., Debra A. Goldman, Alexander N. Shoushtari, Allison Betof Warner, Margaret K. Callahan, Parisa Momtaz, James W. Smithy, et al. 2022. “Adaptive Dosing of Nivolumab + Ipilimumab Immunotherapy Based Upon Early, Interim Radiographic Assessment in Advanced Melanoma (The ADAPT-IT Study).” Journal of Clinical Oncology40 (10): 1059–67. https://doi.org/10.1200/jco.21.01570."
  },
  {
    "objectID": "jc.html#articles-3",
    "href": "jc.html#articles-3",
    "title": "Journal Club",
    "section": "2021 Articles",
    "text": "2021 Articles\n\n\n\n\n\n\nJanuary - December 2021\n\n\n\n\n\n\nDecember\nHarms, Paul W., Monique E. Verhaegen, Kevin Hu, Steven M. Hrycaj, May P. Chan, Chia-Jen Liu, Marina Grachtchouk, Rajiv M. Patel, Aaron M. Udager, and Andrzej A. Dlugosz. 2021. “Genomic Evidence Suggests That Cutaneous Neuroendocrine Carcinomas Can Arise from Squamous Dysplastic Precursors.” Modern Pathology 35 (4): 506–14. https://doi.org/10.1038/s41379-021-00928-1.\n\n\nNovember\nTawbi, Hussein A, Peter A Forsyth, F Stephen Hodi, Christopher D Lao, Stergios J Moschos, Omid Hamid, Michael B Atkins, et al. 2021. “Safety and Efficacy of the Combination of Nivolumab Plus Ipilimumab in Patients with Melanoma and Asymptomatic or Symptomatic Brain Metastases (CheckMate 204).” Neuro-Oncology 23 (11): 1961–73. https://doi.org/10.1093/neuonc/noab094.\n\n\nOctober\nHsueh, Eddy C., James R. DeBloom, Jonathan H. Lee, Jeffrey J. Sussman, Kyle R. Covington, Hillary G. Caruso, Ann P. Quick, Robert W. Cook, Craig L. Slingluff, and Kelly M. McMasters. 2021. “Long-Term Outcomes in a Multicenter, Prospective Cohort Evaluating the Prognostic 31-Gene Expression Profile for Cutaneous Melanoma.” JCO Precision Oncology, no. 5 (November): 589–601. https://doi.org/10.1200/po.20.00119.\n\n\nSeptember\nWilmas, Kelly M., Wesley B. Garner, Matthew T. Ballo, Susan L. McGovern, and Deborah F. MacFarlane. 2021a. “The Role of Radiation Therapy in the Management of Cutaneous Malignancies. Part I: Diagnostic Modalities and Applications.” Journal of the American Academy of Dermatology 85 (3): 539–48. https://doi.org/10.1016/j.jaad.2021.05.058. ———. 2021b. “The Role of Radiation Therapy in the Management of Cutaneous Malignancies. Part II: When Is Radiation Therapy Indicated?” Journal of the American Academy of Dermatology 85 (3): 551–62. https://doi.org/10.1016/j.jaad.2021.05.057.\n\n\nAugust\nPuebla-Tornero, Laura, Luis Antonio Corchete-Sánchez, Alberto Conde-Ferreirós, Natalia García-Sancha, Roberto Corchado-Cobos, Concepción Román-Curto, and Javier Cañueto. 2021. “Performance of Salamanca Refinement of the T3-AJCC8 Versus the Brigham and Women’s Hospital and Tübingen Alternative Staging Systems for High-Risk Cutaneous Squamous Cell Carcinoma.” Journal of the American Academy of Dermatology 84 (4): 938–45. https://doi.org/10.1016/j.jaad.2020.12.020.\n\n\nJuly\nFarberg, Aaron S., Mary A. Hall, Leah Douglas, Kyle R. Covington, Sarah J. Kurley, Robert W. Cook, and Scott M. Dinehart. 2020. “Integrating Gene Expression Profiling into NCCN High-Risk Cutaneous Squamous Cell Carcinoma Management Recommendations: Impact on Patient Management.” Current Medical Research and Opinion 36 (8): 1301–7. https://doi.org/10.1080/03007995.2020.1763284.\n\n\nJune\nStratigos, Alexander J, Aleksandar Sekulic, Ketty Peris, Oliver Bechter, Sorilla Prey, Martin Kaatz, Karl D Lewis, et al. 2021. “Cemiplimab in Locally Advanced Basal Cell Carcinoma After Hedgehog Inhibitor Therapy: An Open-Label, Multi-Centre, Single-Arm, Phase 2 Trial.” The Lancet Oncology 22 (6): 848–57. https://doi.org/10.1016/s1470-2045(21)00126-1.\n\n\nMay\nAndruska, Neal, Benjamin W. Fischer-Valuck, Lily Mahapatra, Randall J. Brenneman, Hiram A. Gay, Wade L. Thorstad, Ryan C. Fields, Kelly M. MacArthur, and Brian C. Baumann. 2021. “Association Between Surgical Margins Larger Than 1 Cm and Overall Survival in Patients With Merkel Cell Carcinoma.” JAMA Dermatology 157 (5): 540. https://doi.org/10.1001/jamadermatol.2021.0247.\n\n\nApril\nCho, Hyunje G., Karen Y. Kuo, Shufeng Li, Irene Bailey, Sumaira Aasi, Anne Lynn S. Chang, Anthony E. Oro, Jean Y. Tang, and Kavita Y. Sarin. 2018. “Frequent Basal Cell Cancer Development Is a Clinical Marker for Inherited Cancer Susceptibility.” JCI Insight 3 (15). https://doi.org/10.1172/jci.insight.122744.\n\n\nMarch\nMorgan, Frederick C., Emily Stamell Ruiz, Pritesh S. Karia, Robert J. Besaw, Victor A. Neel, and Chrysalyne D. Schmults. 2021. “Brigham and Women’s Hospital Tumor Classification System for Basal Cell Carcinoma Identifies Patients with Risk of Metastasis and Death.” Journal of the American Academy of Dermatology 85 (3): 582–87. https://doi.org/10.1016/j.jaad.2021.01.052.\n\n\nFebruary\nMorgan, Frederick C., Emily Stamell Ruiz, Pritesh S. Karia, Robert J. Besaw, Victor A. Neel, and Chrysalyne D. Schmults. 2020. “Factors Predictive of Recurrence, Metastasis, and Death from Primary Basal Cell Carcinoma 2 Cm or Larger in Diameter.” Journal of the American Academy of Dermatology 83 (3): 832–38.\n\n\nJanuary\nDanesh, Melissa J., Tyler D. Menge, Lydia Helliwell, Meera Mahalingam, and Abigail Waldman. 2020. “Adherence to the National Comprehensive Cancer Network Criteria of Complete Circumferential Peripheral and Deep Margin Assessment in Treatment of High-Risk Basal and Squamous Cell Carcinoma.” Dermatologic Surgery 46 (12): 1473–80. https://doi.org/10.1097/dss.0000000000002354."
  },
  {
    "objectID": "jc.html#articles-4",
    "href": "jc.html#articles-4",
    "title": "Journal Club",
    "section": "2020 Articles",
    "text": "2020 Articles\n\n\n\n\n\n\nJanuary - December 2020\n\n\n\n\n\n\nDecember\nTarabadkar, Erica S., Teresa Fu, Kristina Lachance, Daniel S. Hippe, Thomas Pulliam, Hannah Thomas, Janet Y. Li, et al. 2021. “Narrow Excision Margins Are Appropriate for Merkel Cell Carcinoma When Combined with Adjuvant Radiation: Analysis of 188 Cases of Localized Disease and Proposed Management Algorithm.” Journal of the American Academy of Dermatology 84 (2): 340–47. https://doi.org/10.1016/j.jaad.2020.07.079.\n\n\nNovember\nOwen, Joshua L, Nour Kibbi, Brandon Worley, Ryan C Kelm, Jordan V Wang, Christopher A Barker, Ramona Behshad, et al. 2019. “Sebaceous Carcinoma: Evidence-Based Clinical Practice Guidelines.” The Lancet Oncology 20 (12): e699–714. https://doi.org/10.1016/s1470-2045(19)30673-4.\n\n\nOctober\nSingh, Neha, Nora A. Alexander, Kristina Lachance, Christopher W. Lewis, Aubriana McEvoy, Gensuke Akaike, David Byrd, et al. 2021. “Clinical Benefit of Baseline Imaging in Merkel Cell Carcinoma: Analysis of 584 Patients.” Journal of the American Academy of Dermatology 84 (2): 330–39. https://doi.org/10.1016/j.jaad.2020.07.065.\n\n\nSeptember\nD’Arcy, Monica E, David Castenson, Charles F Lynch, Amy R Kahn, Lindsay M Morton, Meredith S Shiels, Ruth M Pfeiffer, and Eric A Engels. 2020. “Risk of Rare Cancers Among Solid Organ Transplant Recipients.” JNCI: Journal of the National Cancer Institute, May. https://doi.org/10.1093/jnci/djaa078.\n\n\nAugust\nSchauder, David M., Jinwan Kim, and Rajiv I. Nijhawan. 2020. “Evaluation of the Use of Capecitabine for the Treatment and Prevention of Actinic Keratoses, Squamous Cell Carcinoma, and Basal Cell Carcinoma.” JAMA Dermatology 156 (10): 1117. https://doi.org/10.1001/jamadermatol.2020.2327.\n\n\nJuly\nLobl, Marissa B., Dillon Clarey, Shauna Higgins, Adam Sutton, Laura Hansen, and Ashley Wysong. 2020. “Targeted Next-Generation Sequencing of Matched Localized and Metastatic Primary High-Risk SCCs Identifies Driver and Co-Occurring Mutations and Novel Therapeutic Targets.” Journal of Dermatological Science 99 (1): 30–43. https://doi.org/10.1016/j.jdermsci.2020.05.007.\n\n\nJune\nWysong, Ashley, Jason G. Newman, Kyle R. Covington, Sarah J. Kurley, Sherrif F. Ibrahim, Aaron S. Farberg, Anna Bar, et al. 2021. “Validation of a 40-Gene Expression Profile Test to Predict Metastatic Risk in Localized High-Risk Cutaneous Squamous Cell Carcinoma.” Journal of the American Academy of Dermatology 84 (2): 361–69. https://doi.org/10.1016/j.jaad.2020.04.088.\n\n\nMay\nTopalian, Suzanne L., Shailender Bhatia, Asim Amin, Ragini R. Kudchadkar, William H. Sharfman, Celeste Lebbé, Jean-Pierre Delord, et al. 2020. “Neoadjuvant Nivolumab for Patients With Resectable Merkel Cell Carcinoma in the CheckMate 358 Trial.” Journal of Clinical Oncology 38 (22): 2476–87. https://doi.org/10.1200/jco.20.00201.\n\n\nMarch\nSekulic, Aleksandar, Michael R. Migden, Nicole Basset-Seguin, Claus Garbe, Anja Gesierich, Christopher D. Lao, Chris Miller, et al. 2017. “Long-Term Safety and Efficacy of Vismodegib in Patients with Advanced Basal Cell Carcinoma: Final Update of the Pivotal ERIVANCE BCC Study.” BMC Cancer 17 (1). https://doi.org/10.1186/s12885-017-3286-5.\n\n\nFebruary\nRuiz, Emily Stamell, Shlomo A. Koyfman, Syril Keena T. Que, Jason Kass, and Chrysalyne D. Schmults. 2020. “Evaluation of the Utility of Localized Adjuvant Radiation for Node-Negative Primary Cutaneous Squamous Cell Carcinoma with Clear Histologic Margins.” Journal of the American Academy of Dermatology 82 (2): 420–29. https://doi.org/10.1016/j.jaad.2019.07.048."
  },
  {
    "objectID": "jc.html#articles-5",
    "href": "jc.html#articles-5",
    "title": "Journal Club",
    "section": "2019 Articles",
    "text": "2019 Articles\n\n\n\n\n\n\nApril - December 2019\n\n\n\n\n\n\nDecember\nKnepper, Todd C., Meagan Montesion, Jeffery S. Russell, Ethan S. Sokol, Garrett M. Frampton, Vincent A. Miller, Lee A. Albacker, et al. 2019. “The Genomic Landscape of Merkel Cell Carcinoma and Clinicogenomic Biomarkers of Response to Immune Checkpoint Inhibitor Therapy.” Clinical Cancer Research 25 (19): 5961–71. https://doi.org/10.1158/1078-0432.ccr-18-4159.\n\n\nNovember\nHarris, Brianna N., Patrik Pipkorn, Ky Nam Bai Nguyen, Ryan S. Jackson, Shyam Rao, Michael G. Moore, D. Gregory Farwell, and Arnaud F. Bewley. 2019. “Association of Adjuvant Radiation Therapy With Survival in Patients With Advanced Cutaneous Squamous Cell Carcinoma of the Head and Neck.” JAMA OtolaryngologyHead & Neck Surgery145 (2): 153. https://doi.org/10.1001/jamaoto.2018.3650.\nStrassen, Ulrich, Benedikt Hofauer, Christian Jacobi, and Andreas Knopf. 2016. “Management of Locoregional Recurrence in Cutaneous Squamous Cell Carcinoma of the Head and Neck.” European Archives of Oto-Rhino-Laryngology 274 (1): 501–6. https://doi.org/10.1007/s00405-016-4243-7.\n\n\nOctober\nMigden, Michael R., Danny Rischin, Chrysalyne D. Schmults, Alexander Guminski, Axel Hauschild, Karl D. Lewis, Christine H. Chung, et al. 2018. “PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma.” New England Journal of Medicine 379 (4): 341–51. https://doi.org/10.1056/nejmoa1805131.\n\n\nSeptember\nFox, Matthew, Marc Brown, Nicholas Golda, Dori Goldberg, Christopher Miller, Melissa Pugliano-Mauro, Chrysalyne Schmults, et al. 2019. “Nodal Staging of High-Risk Cutaneous Squamous Cell Carcinoma.” Journal of the American Academy of Dermatology 81 (2): 548–57. https://doi.org/10.1016/j.jaad.2018.09.006.\n\n\nAugust\nRuiz, Emily Stamell, Pritesh S. Karia, Robert Besaw, and Chrysalyne D. Schmults. 2019. “Performance of the American Joint Committee on Cancer Staging Manual, 8th Edition Vs the Brigham and Women’s Hospital Tumor Classification System for Cutaneous Squamous Cell Carcinoma.” JAMA Dermatology 155 (7): 819. https://doi.org/10.1001/jamadermatol.2019.0032.\n\n\nJuly\nGore, Sinclair M., Douglas Shaw, Richard C. W. Martin, Wendy Kelder, Kathryn Roth, Roger Uren, Kan Gao, et al. 2015. “Prospective Study of Sentinel Node Biopsy for High-Risk Cutaneous Squamous Cell Carcinoma of the Head and Neck.” Head & Neck 38 (S1): E884–89. https://doi.org/10.1002/hed.24120.\n\n\nJune\nMiller, Natalie J., Candice D. Church, Steven P. Fling, Rima Kulikauskas, Nirasha Ramchurren, Michi M. Shinohara, Harriet M. Kluger, et al. 2018. “Merkel Cell Polyomavirus-Specific Immune Responses in Patients with Merkel Cell Carcinoma Receiving Anti-PD-1 Therapy.” Journal for ImmunoTherapy of Cancer 6 (1). https://doi.org/10.1186/s40425-018-0450-7.\n\n\nMay\nRosenberg, Abby R., Mary Tabacchi, Kenneth H. Ngo, Michael Wallendorf, Ilana S. Rosman, Lynn A. Cornelius, and Shadmehr Demehri. 2019. “Skin Cancer Precursor Immunotherapy for Squamous Cell Carcinoma Prevention.” JCI Insight 4 (6). https://doi.org/10.1172/jci.insight.125476.\n\n\nApril\nPorceddu, Sandro Virgilio, Mathias Bressel, Michael Geoffrey Poulsen, Adam Stoneley, Michael John Veness, Lizbeth Moira Kenny, Chris Wratten, et al. 2018. “Postoperative Concurrent Chemoradiotherapy Versus Postoperative Radiotherapy in High-Risk Cutaneous Squamous Cell Carcinoma of the Head and Neck: The Randomized Phase III TROG 05.01 Trial.” Journal of Clinical Oncology 36 (13): 1275–83. https://doi.org/10.1200/jco.2017.77.0941."
  },
  {
    "objectID": "index.html",
    "href": "index.html",
    "title": "About SoCO",
    "section": "",
    "text": "The Society of Cutaneous Oncology (SoCO) is a collective of clinicians and investigators committed to improving outcomes in patients with skin cancer. Our mission is threefold: 1) to interpret evidence to help shape best practices, 2) to support members in producing high-quality reproducible science, and 3) educate future generations of clinical oncologists and scientific investigators dedicated to skin cancer. To fulfill those objectives the SoCO: 1) is the publisher of Journal of Cutaneous Oncology (JoCO), an open access journal whose scope is specific to skin cancer, 2) hosts a recurring monthly journal club and 3) supports a open forum for research discussions and presentations that convenes several times per year."
  }
]